Biocon Limited — Q2 FY26
Biocon delivered a strong Q2 FY26 with consolidated revenue of ₹4,296 crore (+20% YoY) and EBITDA of ₹928 crore (+29% YoY), driven by biosimilars (+25% YoY) and generics (+24% Y...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY26
Liraglutide U.S. approval expected this fiscal
Liraglutide U.S. file is under FDA review with a target action date; approval and launch expected during FY26.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY26
Denosumab U.S. approval by end of calendar 2025
Biocon Biologics expects U.S. FDA approval for denosumab before the end of calendar 2025.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY26
Semaglutide filings in Q2 FY26 for emerging markets and Canada
Semaglutide will be filed in Q2 FY26 in many emerging markets and Canada, with best-case approval by end of calendar 2026.
Delayed
The current-quarter record did not contain enough evidence of delivery; the item remains delayed for follow-up.
heuristic_v1